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Abstract
Introduction: The kidneys play an essential role in PRRT. The infusion of amino acids could reduce uptake in the kidney of radiolabelled 
peptides. 
The purpose of this study was to determine the extent of kidney damage post PRRT.
Material and methods: 53 patients, with disseminated neuroendocrine tumours (NET), received 3–5 cycles of up to a maximum 7.4 GBq/m2 
calculated dose of 90Y-DOTATATE (n = 25) and 90Y/177Lu-DOTATATE (n = 28). Creatinine levels were measured and glomerular filtration 
rates (GFR) were calculated. A mixed amino acid infusion was used for nephroprotection. 
Results: Patients treated with 90Y-DOTATATE had a mean creatinine level of 0.77 ± 0.19 mg/dL and a mean GFR (mL/min/1.73 m2) of 
103.6 ± 30.8. Patients treated with 90Y/177Lu-DOTATATE had a mean creatinine level of 0.92 ± 0.33 mg/dL and a mean GFR of 84.7 ± 26.3.
In the follow up, among patients treated with 90Y-DOTATATE and 90Y/177Lu-DOTATATE, the mean GFR level at 12 months was 101.2 ± 
± 31.3 v. 83.9 ± 25.2, at 24 months 80.2 ± 32.7 v. 77.2 ± 31.1, at 36 months 78.9 ± 42.1 v. 67.5 ± 9.7, and 48 months 59.7 ± 15.2 v. 72.6 ± 11.2. 
The mean yearly decrease in GFR was 4.5 mL in all treated patients; for patients treated with 90Y-DOTATATE and 90Y/177Lu-DOTATATE it 
was 6.8 v. 3.0, respectively.
Conclusions: 90Y/177Lu-DOTATATE treatment induced statistically significantly less change in kidney function compared to 90Y-DOTATATE. 
(Endokrynol Pol 2013; 64 (1): 13–20)
Key words: somatostatin receptors, peptide receptor radionuclide therapy, neuroendocrine tumours, nephrotoxicity, 90Y-DOTATATE, tandem 
90Y/177Lu-DOTATATE
Streszczenie 
Wstęp: Narządem krytycznym w leczeniu guzów neuroendokrynnych z zastosowaniem znakowanych radioizotopowo analogów so-
matostatyny (PRRT) są nerki. Działanie nefrotoksyczne można ograniczyć, podając roztwór aminokwasów w formie wlewu dożylnego.
Celem pracy była analiza stopnia uszkodzenia nerek po PRRT w ciągu pierwszych czterech lat po leczeniu. 
Materiał i metody: Do badania włączono 53 chorych, z rozpoznanym rozsianym procesem neuroendokrynnym (NET). Chorzy otrzymali 
7,4 GBq/m2 90Y-DOTATATE (n = 25) lub 90Y/177Lu-DOTATATE (n = 28) w 3–5 cyklach. Radiofarmaceutyk podawano w trakcie wlewu i.v. 
roztworu aminokwasów. Oceniano stężenie kreatyniny, na podstawie którego obliczano wartość filtracji kłębuszkowej (GFR). 
Wyniki: Przed leczeniem w grupie chorych leczonych 90Y-DOTATATE stężenie kreatyniny wynosiło 0,77 ± 0,19 (mg/dl), natomiast GFR 
103,6 ± 30,8 (ml/min/1,73 m2). W grupie leczonej 90Y/177Lu-DOTATATE stężenie kreatyniny wynosiło 0,92 ± 0,33 i GFR 84,7 ± 26,3. Nie 
stwierdzono statystycznie znamiennej różnicy w wartościach badanych parametrów między obydwiema grupami. 
Po 12 miesiącach wartość GFR w grupie leczonej 90Y-DOTATATE i grupie leczonej 90Y/177Lu-DOTATATE wynosiła odpowiednio: 101 ± 
± 31,3 oraz 83,9 ± 25,2. Po 24 miesiącach odpowiednio: 80,2 ± 32,7 i 77,2 ± 31,1. Po 36 miesiącach odpowiednio 78,9 ± 42,1 i 67,5 ± 9,7. 
Po 48 miesiącach odpowiednio: 59,7 ± 15,2 i 72,6 ± 11,2. Średni spadek GFR dla wszystkich chorych wynosił 4,5 ml/rok, dla chorych leczo-
nych 90Y-DOTATATE – 6,8 ml/rok, natomiast dla chorych leczonych 90Y/177Lu-DOTATATE — 3,0 ml/rok
Wnioski: Leczenie z zastosowaniem 90Y/177Lu-DOTATATE jest związane z istotnie mniejszym statystycznie uszkodzeniem czynności nerek 
w porównaniu do leczenia z zastosowaniem 90Y-DOTATATE. (Endokrynol Pol 2013; 64 (1): 13–20)
Słowa kluczowe: receptory somatostatynowe, terapia znakowanymi izotopowo analogami somatostatyny, guzy neuroendokrynne, 
nefrotoksyczność, 90Y-DOTATATE, 90Y/177Lu-DOTATATE
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Introduction 
PRRT, using radiolabelled somatostatin analogues, has 
shown promising results in the treatment of patients with 
inoperable or metastatic NET. However, PRRT may adversely 
affect the kidneys due to the re-absorption of radiolabelled 
somatostatin analogues in the proximal tubules of nephrons 
[1, 2] and the expression of somatostatin receptors [3]. 
Clinically, renal failure and end-stage renal disease 
(ESRD) have been documented post PRRT with 90Y-DOTA-
TOC [4, 5]. Furthermore, renal damage may occur during 
external beam radiation therapy when absorbed doses reach 
23 Gy or higher [6]. This was confirmed by Milano: a group 
of patients (n = 47) treated with 90Y-DOTATOC received 
a cumulative kidney dose of 27 Gy during six courses [7]. 
Co-administration of amino acids L-lysine and/or 
L-arginine competitively inhibit the proximal tubular 
re-absorption of radiopeptides, reducing uptake by 40%, 
thus offering significant nephroprotection [8]. Moreo-
ver, succinylated gelatin plasma expander Gelofusine 
co-injected with lysine can reduce kidney radiopeptide 
uptake by 62–70% [9, 10]. 
Renal malfunction may appear several years post 
PRRT, potentially coinciding with chronic kidney diseas-
es found more often in the elderly. The age-associated 
decline in GFR during the third decade of life, from 
a peak of about 120 mL/min/1.73 m2, is approximately 
1 mL/min/y/1.73 m2, reaching a mean value of 70 mL/ 
/min/1.73 m2 at the age of 70 [11]. GFR also declines in pa-
tients with additional risk factors: hypertension 2.32–4.1 
mL/min/1.73 m2 [12,13], diabetes 4.7–7.2 mL/min/1.73 m2 
[14,15], and cisplatin chemotherapy ≤ 6 mL/min/1.73 m2 
per year [16]. In addition, post PRRT renal failure may be 
insidious; stages 1–3 of kidney failure are for the most part 
clinically silent. Consequently, it is important to observe 
long term renal function following PRRT. 
In our study, we analysed changes in renal function 
post PRRT with 90Y-DOTATATE and tandem 90Y/177Lu-
DOTATATE. 
Material and methods
This study was approved by the ethical committee of 
the Medical University of Warsaw. All patients gave 
written informed consent.
53 patients with diffuse NETs were enrolled in an un-
controlled study. The 90Y-DOTATATE treatment group 
consisted of 25 patients (11 males and 14 females) with a 
mean age of 57.4 ± 9.9 years, ranging from 37–75 years. 
The 90Y/177Lu-DOTATATE treatment group consisted of 
ten males and 18 females, totalling 28 patients, with a 
mean age of 55 ± 10.9 years, ranging from 39–78 years.
The patients in our study were not randomised, but 
were treated first using 90Y DOTATATE; patients who 
presented later were treated with 90Y/177Lu DOTATATE. 
Subsequently, Cox analysis was used to evaluate the ef-
fects of relevant prognostic factors on the survival times 
in each treatment group, as well as the independency 
of these variables.
GFR was calculated using creatinine-based approxi-
mations based on the modification of diet in renal dis-
ease (MDRD) [17]. Basal creatinine values ranged from 
0.5 to 1.3 mg/dL in the 90Y-DOTATATE treatment group, 
and from 0.5 to 1.9 mg/dL in the 90Y/177Lu-DOTATATE 
treatment group. Basal calculated GFR ranges were 171 
to 43 mL/min in the 90Y-DOTATATE group, and 137 to 
40 mL/min in the 90Y/177Lu-DOTATATE group.
The progression of disease, in both groups, was 
confirmed by CT and by an increase of chromogranin A 
(CgA) concentration in blood. Response to treatment 
was observed by CT and stratified according to the 
Response Evaluation Criteria in Solid Tumours (RE-
CIST). The following inclusion criteria for therapy 
were used:
 — Somatostatin receptor imaging (99mTc-HYNIC-TATE 
or 68Ga-DOTATATE) positive uptake by tumour and 
metastases at least three months prior to inclusion;
 — Histological confirmation of NET tumour, deter-
mined to be inoperable or metastatic;
 — Haemoglobin level (Hb) ≥ 10 g/dL; leukocytes (WBC) 
≥ 2 × 109/L; thrombocytes (PLT) ≥ 90 × 109/L;
 — Calculated GFR > 40 mL/min;
 — Karnofsky Performance Status ≥ 60;
 — Life expectancy > 3 months;
 — No pregnancy or lactation;
 — Interval between chemotherapy and PRRT of at least 
three months.
Treatment
Therapy was performed on an outpatient basis. Treat-
ment sessions were repeated with a total calculated 
maximum dose of 7.4 GBq /m2. The injected activity 
per course equaled 2.2–3.7 GBq. Four patients from 
the 90Y-DOTATATE treatment group and two from the 
90Y/177Lu-DOTATATE treatment group received two ad-
ditional cycles due to recurrence of disease.
With regards to 90Y/177Lu-DOTATATE, 50% of the 
activity was attributed to 90Y-DOTATATE and the other 
50% to 177Lu-DOTATATE. The median period between 
the treatments was 40 and 49 days, respectively. A mixed 
amino-acid infusion, consisting of 11.3 g of arginine 
and 9.0 g lysine (1,000 mL Vamin 18, Fresenius Kabi) 
and Ringer’s solutions (500 mL), was infused over eight 
hours in addition to 200 ml prior to administration of 
the treatment [18, 19]. Ondansetron (8 mg, Zofran, 
Glaxo Wellcome, Atossa, Anpharm S. A.) was given 
intravenously to prevent nausea and vomiting prior to 
the administration of radiopharmaceuticals.
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Evaluation of Results and Assessment of Clinical 
Benefit
Creatinine level was assessed prior to treatment and 
reassessed seven, and 21–30 days after each cycle 
of therapy, and then after three, six, 12, 24, 36, and 
48 months. Renal toxicity was defined by the National 
Cancer Institute.
Statistical methods
Means, standard deviations, and frequencies were used to 
summarise patient characteristics. Linear multi-parameters 
regression models were used to analyse the influence of 
risk factors over time, depending on the changes of GFR. 
Overall survival (OS), event free survival (EFS), and time to 
progression (TTP) were calculated using the Kaplan-Meier 
estimator. They were then compared using the log-rank 
test. Calculations were done using Stata v.10.1 software 
(Stata Statistical Software: Release 10, College Station, TX, 
Stata Corporation LP 2007).
Results
Patient characteristics
The study included 53 Caucasian patients with meta-
static NETs. Medical history revealed common risk 
factors for kidney disease: age > 60 years, diabetes, 
hypertension, and positive family history. Addition-
ally, previous chemotherapy (etoposide + cisplatin or 
streptozocin + 5-fluourouracyl) was evaluated. Refer 
to Table I for detailed patient characteristics.
Outcome of therapy
Median OS, of patients treated with 90Y-DOTATATE, was 
34.2 months and 49.8 months for patients treated with 
90Y/177Lu-DOTATATE (p > 0.05). The median EFS time in 
the 90Y-DOTATATE and the 90Y/177Lu-DOTATATE group 
was 19.3 v. 24.3 months, respectively, while the median TTP 
was 24.2 compared to 24.3 months for the 90Y-DOTATATE 
and the 90Y/177Lu-DOTATATE group respectively. The dif-
ferences were not statistically significant.
Kidney function after treatment with 90Y-DOTA-
TATE and 90Y/177Lu-DOTATATE
Treatment was well tolerated without severe adverse 
events. Baseline mean creatinine level was 0.77 ± 0.19 
mg/dL and GFR (mL/min/1.73 m2) was 103.6 ± 30.8 
in patients treated with 90Y-DOTATATE. In contrast, 
baseline mean creatinine level of 0.92 ± 0.33 mg/dL and 
GFR of 84.7 ± 26.3 were noted in patients treated with 
90Y/177Lu-DOTATATE (Fig. 1). 
Upon follow up, patients in the 90Y-DOTATATE 
and 90Y/177Lu-DOTATATE group had, at six months, 
creatinine levels (mg/dL) of 0.77 ± 0.24 v. 0.86 ± 0.32, at 
12 months 0.8 ± 0.25 v. 0.94 ± 0.43, at 24 months 
0.97 ± 0.36 v. 1.07 ± 0.55, at 36 months 1.07 ± 0.55 v. 
1.03 ± 0.22, and at 48 months 1.3 ± 0.5 v. 0.96 ± 0.16. 
The mean GFR level (mL/min/1.73 m2) at six months 
was 105.6 ± 35.1 v. 92.6 ± 33.9, at 12 months 101.2 ± 31.3 
v. 83.9 ± 25.2, at 24 months 80.2 ± 32.7 v. 77.2 ± 31.1, at 
36 months 78.9 ± 42.1 v. 67.5 ± 9.7, and at 48 months 
59.7 ± 15.2 v. 72.6 ± 11.2.
The median changes of GFR at 48 months are pre-
sented in Figure 2 and detailed changes in particular 
patients in both treatment groups in Tables II and III.
The yearly mean increase in creatinine level for the 
entire study group was 0.056 mg/dL. The yearly decrease 
in GFR, calculated by a linear regression model, was 
4.5 mL/min/1.73 m2 in all treated patients. The decrease in 
GFR in patients treated with 90Y-DOTATATE and 90Y/177Lu-
DOTATATE was 6.8 v. 3 mL/min/1.73 m2 per year (p < 0.05). 
It was observed that patients from both groups 
with more than two risk factors demonstrated the 
largest statistically significant changes in GFR (Fig. 3). 
Multi-parameter regression models (including pre-
vious reported risk factors) revealed GFR statisti-
cally significant changes depending on the type of 
therapy, hypertension and previous chemotherapy 
(Table IV). GFR declination percent upon follow-up 
was significantly lower in the group treated with 
90Y/177Lu-DOTATATE (Fig. 4).
Grade 1 nephrotoxicity was seen in 2/25 patients 
treated with 90Y-DOTATATE and 2/28 in the group treated 
with 90Y/177Lu-DOTATATE. Grade 2 nephrotoxicity was 
seen in 3/25 patients and 1/28 patients, respectively. Grade 
3 and 4 nephrotoxicity was not observed in both groups.
Table I. Patient characteristics
Tabela I. Charakterystyka pacjentów
90Y-DOTATATE 
N = 25
90Y /177Lu -DOTATATE 
N = 28
Age range 
Mean ± SD
37–75 
57.4 ± 9.9
39–73 
55 ± 10.9
Sex: Female 14 (56%) 18 (64%)
Age > 40 22 (88%) 25 (89%)
Age > 60 10 (40%) 13 (46%)
Chemotherapy 9 (36%) 9 (32%)
Diabetes mellitus 5 (20%) 8 (29%)
Hypertension 15 (60%) 20 (71%)
Primary tumours
Foregut 16 (64%) 14 (50%)
Midgut 6 (24%) 9 (32%)
Hindgut 2 (8%) 1 (4%)
Unknown primary 1 (4%) 2 (7%)
Other 0 2 (7%)
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Mild nausea occurred at equal frequencies in both 
groups; it affected 38% of the entire population and was 
reported upon administration of radiopharmaceuticals 
and amino-acids infusion. All cases of nausea and vomit-
ing responded to ondansetron. Hyperkalemia was not 
observed clinically nor in blood tests. 
Discussion
177Lu and 90Y demonstrate different physical properties. 
These differences include half-life, path length, and type 
of energy emission. 90Y emits b-particles with longer path 
lengths and higher energies. 177Lu has a shorter b-particle 
range, and longer half-life, resulting in lower kidney 
re-absorption and reduction of renal toxicity [20]. In the 
literature, nephrotoxicity after PRRT with 90Y -DOTA-
TOC has been recognised as an important clinical problem 
which limits therapy [21–25]. Cumulative experience with 
90Y-DOTATOC was reported by the Basel group [26]. Four 
cases of early renal insufficiency and two additional cases of 
delayed renal failure in studies without infusion of amino 
acids for renal protection were observed. In later studies, only 
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Figure 2. Box-plot of changes in GFR at six, 12, 24, 36 and 48 months follow up in group treated with 90Y-DOTATATE and 90Y/177Lu-
DOTATATE. Line is presented as median changes
Rycina 2. Wykres zmian GFR w kontroli po 6, 12, 24 ,36 i 48 miesiącach w grupie leczonej 90Y-DOTATATE lub 90Y/177Lu-DOTATATE. 
Linia prezentuje medianę
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Figure 1. Baseline GFR of persons in the two groups treated with 90Y-DOTATATE and  90Y/177Lu-DOTATATE before PRRT. Line is 
presented as median 
Rycina 1. Wyjściowe (przed terapią) wartości GFR dla obu grup leczonych 90Y-DOTATATE lub 90Y/177Lu-DOTATATE. Linia prezentuje medianę
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Table II. Number of risk factors and GRF changes after PRRT in group treated with 90Y-DOTATATE
Tabela II. Występujące czynniki ryzyka i zmiany GFR po PRRT w grupie leczonej 90Y-DOTATATE
Age Number 
of risk 
factors
Age
> 60
CHT HA DM Total administered 
activity 
[GBq]
GFR baseline 
[mL/min/m2]
GFR follow up 
[mL/min/m2]
1 37 1 + 3.7 161.1 Death in first year
2 59 1 + 14.8 109.9 Death last follow up 12 months  
86.2
3 63 1 + 13.3 96.8 Death last follow up 12 months  
117.2
4 36 1 + 15 86.3 Death last follow up 24 months  
86.3
5 59 1 + 17.8 134.2 134.2 
(48 months)
6 70 2 + + 7.4 90.9 Death in first year
7 50 2 + + 13.3 76.3 70.4 
(48 months)
8 64 2 + + 12.6 107.0 59.3 
(36 months)
9 58 2 + + 22.6 109.1 Death last follow up 36 months  
54.2
10 56 1 + 22.9 81.2 Death last follow up 24 months  
55.7
11 68 3 + + + 14.8 101.7 69.7 
(36 months)
12 65 4 + + + + 13.3 43.7 Death last follow up 12 months  
55.5
13 46 0 13.3 163.6 135.7 
(24 months)
14 44 0 14.8 110.0 Death last follow up 12 months  
120.2
15 61 2 + + 14.8 171.7 Death last follow up 24 months  
145.6
16 66 2 + + 6.7 70.2 Death in first year
17 44 2 + + 14.1 128.1 61 
(48 months)
18 55 1 + 13.3 79.2 Death last follow up 36 months  
64.1
19 55 1 + 13.3 111.5 Death last follow up 24 months  
93.1
20 56 2 + + 3.7 92.8 Death in first year
21 47 0 19.2 71.3 64.7 
(48 months)
22 60 3 + + + 17.8 72.6 33.5 
(48 months)
23 70 3 + + + 14.1 101.6 68.9 
(48 months)
24 59 1 + 20.7 100.8 Death last follow up 24 months  
69.7
25 68 1 + 11.8 119.3 69.7 
(24 months)
CHT — chemotherapy; HA — hypertension; DM — diabetes mellitus
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Table III. Number of risk factors and GRF changes after PRRT in group treated with 90Y /177Lu-DOTATATE 
Tabela III. Występujące czynniki ryzyka i zmiany GFR po PRRT w grupie leczonej 90Y/177Lu-DOTATATE
Age Number of 
risk factors
Age 
 > 60
CHT HA DM Total administered activity 
[GBq]
GFR baseline 
[mL/min/m2]
GFR follow up 
[mL/min/m2]
1 39 2 + + 14.1 133.4 Death last follow up 24 months  
64.2
2 57 2 + + 23.3 70.4 64.5  
(48 months)
3 62 2 + + 21.5 98.2 67.4 
(48 months)
4 58 2 + + 13.3 76.1 60.5 
(48 months)
5 69 4 + + + + 14.8 40.2 45.8 
(36 months)
6 45 1 + 13 82.4 82.4 
(24 months)
7 72 3 + + + 13.3 79.5 67.1 
(48 months)
8 62 2 + + 13 67.4 77.2 
(48 months)
9 62 2 + + 11.1 86.4 Death last follow up 24 months  
85.4
10 67 2 + + 16.7 71.7 64.0 
(36 months)
11 50 1 + 14.8 80.3 84.1 
(48 months)
12 40 0 17 89.6 69.2 
(48 months)
13 38 1 + 10.4 118.9 Death last follow up 24 months  
118.9
14 67 2 + + 14.8 87.3 76.0 
(48 months)
15 57 2 + + 14.8 116.2 Death last follow up 12 months  
118.6
16 40 0 11.1 58.5 58.5 
(48 months)
17 42 1 + 12.6 64.6 52.4 
(48 months)
18 47 0 14.8 137.4 95.3 
(36 months)
19 64 2 + + 14.8 81.8 71.6 
(48 months)
20 59 2 + + 10.4 52.4 54.0 
(48 months)
21 63 1 + 13 132.4 89.8 
(24 months)
22 63 4 + + + + 14.8 58 Death last follow up 24 months  
54.3
23 44 1 + 13 93.5 Death last follow up 12 months  
86.6
24 68 4 + + + + 11.1 105.7 Death in first year
25 69 3 + + + 9.6 50.5 Death last follow up 24 months  
22.2
26 60 2 + + 14.1 58.1 63.0 
(24 months)
27 52 1 + 13 107.4 123.4 
(24 months)
28 53 1 + 14.1 74.4 Death in first year
CHT — chemotherapy; HA — hypertension; DM — diabetes mellitus
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a single patient developed late grade 2 renal toxicity when 
nephroprotecting agents, such as amino acids, were added 
during therapy [27]. In Milan’s study, 256 patients received 
amino acids [28] and no acute renal toxicity was reported. 
One patient developed grade 2 toxicity, two patients devel-
oped grade 1 toxicity, and two patients developed transient 
grade 1 toxicity. Bodei at al. [29] observed patients treated with 
90Y-DOTATOC: 7/23 developed grade 1 toxicity, 1/23 patients 
developed grade 2 toxicity, and 1/23 patients developed grade 
3 toxicity. A large study conducted by Imhof et al., consisting 
of 1,109 patients, demonstrated 9.2% permanent renal toxic-
ity with grades 4 to 5; initial renal uptake was predictive for 
severe renal toxicity [30]. In the 177Lu-DOTATATE treatment 
group, renal toxicity was not observed [31]. A 2.5% solution 
of arginine and lysine has been used for nephroprotection 
in published data. This solution was not available in Poland. 
Consequently, a commercially available mixed amino-acid 
solution was used. In our study, nephrotoxicity occurred at a 
similar rate compared to reported data. Grade 1 nephrotoxic-
ity was observed in 2/25 patients treated with 90Y-DOTATATE 
and 2/28 in the group treated with 90Y/177Lu-DOTATATE. 
Grade 2 nephrotoxicity was seen in 3/25 patients and 1/28 
patients, respectively. Grades 3 and 4 were not observed.
Despite nephroprotection, loss of renal function can 
occur post PRRT, with a creatinine clearance loss of about 
3.8% per year for 177Lu-DOTATATE and 7.3% per year for 
90Y-DOTATOC [30]. Grade 4 and 5 kidney toxicity has been 
reported in 9.2% of patients treated with 90Y-DOTATOC [32]. 
The influence of additional risk factors on nephrotoxic-
ity presents another dilemma. The clinical observation of 
renal damage post PRRT, in the study by Valkema et al., 
revealed five risk factors: cumulative renal absorbed doses 
of more than 25 Gy, diabetes, hypertension, age > 60 years 
and a renal radiation dose > 14 Gy per cycle [32]. Similar 
negative influences of hypertension, diabetes mellitus and 
previous chemotherapy were observed by Barone et al. 
[33] and by Bodei et al. [29]. 
In our study, we observed significant influences of 
one type of radioisotope therapy, hypertension and 
previous chemotherapy. The influence of diabetes 
mellitus and an age > 60 years were not statistically 
significant. This could be connected to the proportion of 
older patients and good control of diabetes. The major-
ity of patients in our study had one or more risk factors 
for renal disease. The significant GFR changes were 
observed among patients with two or more risk factors.
The reported biological effective dose threshold for 
renal toxicity in patients with risk factors was 28 Gy. In 
patients without risk factors, the threshold for toxicity 
was 40 Gy [29]. Clinical experience and earlier dosimetry 
studies have indicated that the renal dose threshold 
does not accurately correlate with the renal toxicity 
observed in patients undergoing PRRT [30]. 
The limitations of this study were the small number 
of patients and the lack of dosimetry. Dosimetry is still 
an open problem for yttrium and tandem therapy. For 
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PRRT with yttrium-90, dosimetry cannot be reconstructed 
from the bremsstrahlung images. For PRRT with tandem 
isotopes, different physical properties of isotopes used are 
presented. However, in our study there was no observed 
grade 3 and 4 renal toxicity, using 200 mCi (7.4 GBq) doses 
per m2. Analysis of GFR decline demonstrated that the 
toxicity of PRRT is comparable to the influence of nepho-
toxicity as a consequence of other risk factors.
Reports of end-stage renal failure during PRRT treat-
ment have appeared in the past, particularly in patients 
receiving doses > 200 mCi (7.4 GBq/m2) [4,5]. Currently, 
this is not observed due to inclusion of nephroprotec-
tive agents during therapy. Infusion of amino acid used 
for nephroprotection can cause nausea, vomiting and 
hyperkalemia. Few adverse reactions were reported 
during this study. Mild nausea was observed in 38% of 
patients and vomiting in 19%, with equal frequency in 
both groups. Hyperkalemia did not occur in our investi-
gation. Nonetheless, it was reported in previous studies 
in which patients received a total dose of 75 g lysine [8]. 
The evolution of nephroprotection during PRRT 
includes novel combinations of agents that reduce renal 
retention of radiolabelled peptides or the development 
of new somatostatin analogues less susceptible to renal 
retention. There is a need for standardisation of therapy 
protocols and multicentre studies in order to enhance the 
clinical value of PRRT in the advent of various other new 
oncological treatments.
Conclusions
90Y/177Lu-DOTATATE treatment induced statistically 
significantly less change in kidney function than 90Y-
DOTATATE. On the basis of published data regarding 
chronic kidney disease, the change of renal function in 
patients after PRRT is comparable to that of any other 
progressive chronic kidney disease. 
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